Lu Chaocheng, Liu Mengjiao, Fu Hualin, Zhang Wei, Peng Guangneng, Zhang Yanli, Cao Hang, Luo Li
Department of Pharmacy, College of Veterinary Medicine, Sichuan Agriculture University, Ya'an, Sichuan 625014, China.
Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Ya'an 625014, China.
Eur J Pharm Sci. 2015 Sep 18;77:24-8. doi: 10.1016/j.ejps.2015.05.014. Epub 2015 May 14.
Side effects and drug residues are major concerns affecting hormone therapy of bovine reproductive diseases. Fertility-promoting intrauterine infusion liquid (FPL), an effective alternative to hormone therapy, is associated with short retention time and low therapeutic efficacy. To address these problems, we developed a thermosensitive in situ gel based on poloxamer 407 for local uterine administration. To achieve the desired gelling temperature and enhance local retention property, we added poloxamer 188 and HPMC to the formulation containing poloxamer 407 and FPL. After screening was performed, the optimized formulation showed good temperature sensitivity in vitro and in vivo. Gelation temperature was approximately 27°C. In vitro release tests showed that icariin (the major active compound in FPL) was slow released from in situ forming gel. After the gel was locally administered, uterine and ovarian indexes were significantly increased in the gel group compared with the control group (P<0.05). The serum estradiol level of the gel group was significantly higher than that of the control group (P<0.01). Histological evaluation did not show mucosa irritation in the gel group. Therefore, the proposed in situ forming gel system based on poloxamer 407 is a promising local drug delivery system to treat bovine uterine diseases.
副作用和药物残留是影响牛生殖疾病激素治疗的主要问题。促生育宫内输液液(FPL)作为激素治疗的有效替代方案,存在保留时间短和治疗效果低的问题。为了解决这些问题,我们开发了一种基于泊洛沙姆407的热敏原位凝胶用于子宫局部给药。为了达到所需的胶凝温度并增强局部保留性能,我们在含有泊洛沙姆407和FPL的制剂中添加了泊洛沙姆188和羟丙基甲基纤维素。经过筛选,优化后的制剂在体外和体内均表现出良好的温度敏感性。胶凝温度约为27°C。体外释放试验表明,淫羊藿苷(FPL中的主要活性化合物)从原位形成凝胶中缓慢释放。凝胶局部给药后,与对照组相比,凝胶组子宫和卵巢指数显著增加(P<0.05)。凝胶组血清雌二醇水平显著高于对照组(P<0.01)。组织学评估未显示凝胶组有黏膜刺激。因此,所提出的基于泊洛沙姆407的原位形成凝胶系统是一种有前景的治疗牛子宫疾病的局部给药系统。